We are live on ! Find out more
TEVA icon

Teva Pharmaceutical Industries

538 hedge funds and large institutions have $9.5B invested in Teva Pharmaceutical Industries in 2017 Q3 according to their latest regulatory filings, with 66 funds opening new positions, 172 increasing their positions, 219 reducing their positions, and 170 closing their positions.

New
Increased
Maintained
Reduced
Closed

4.6% less ownership

Funds ownership: 53.58% → 48.98% (-4.6%)

17% less funds holding

Funds holding: 651 → 538 (-113)

21% less repeat investments, than reductions

Existing positions increased: 172 | Existing positions reduced: 219

39% less capital inflows, than outflows

Capital inflows: $2.07B | Capital outflows: $3.42B

47% less call options, than puts

Call options by funds: $288M | Put options by funds: $548M

59% less funds holding in top 10

Funds holding in top 10: 22 → 9 (-13)

61% less first-time investments, than exits

New positions opened: 66 | Existing positions closed: 170

Holders
538
Holders Change
-113
Holders Change %
-17.36%
% of All Funds
13.37%
Holding in Top 10
9
Holding in Top 10 Change
-13
Holding in Top 10 Change %
-59.09%
% of All Funds
0.22%
New
66
Increased
172
Reduced
219
Closed
170
Calls
$288​M
Puts
$548​M
Net Calls
-⁠$260​M
Net Calls Change
+$4.54​M

TEVA Hedge Fund Activity: Q3 2017 in Review

538 of the 4,024 institutional investors tracked by Wall St. Rank reported a position in Teva Pharmaceutical Industries (TEVA) for Q3 2017, worth a combined $9.5B — down 52% from $19.6B a quarter earlier.

Sellers outnumbered buyers: 170 funds closed out of TEVA and 66 opened new positions — a net loss of 104 holders — while 219 trimmed existing stakes and 172 added.

The largest buyer was Abrams Capital Management, opening a new position worth an estimated $487M. The largest seller was Barrow, Hanley, Mewhinney & Strauss, cutting an estimated $568M.

  • 538 institutional investors held Teva Pharmaceutical Industries (TEVA) as of Q3 2017, down from 651 in Q2 2017.
  • Funds reported $9.5B of Teva Pharmaceutical Industries stock for Q3 2017, down 52% quarter-over-quarter.
  • 66 funds opened new Teva Pharmaceutical Industries positions in Q3 2017 and 170 closed out, a net change of -104 holders.
  • The largest Teva Pharmaceutical Industries buyer in Q3 2017 was Abrams Capital Management, an estimated $487M added.
  • The largest Teva Pharmaceutical Industries seller in Q3 2017 was Barrow, Hanley, Mewhinney & Strauss, an estimated $568M sold.

Based on aggregated 13F filings for Q3 2017.